Regeneron

Results: 62



#Item
31PRESS RELEASE Sanofi and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps Paris and Tarrytown, N.Y. – September 30, [removed]Sanofi and Regeneron Pharma

PRESS RELEASE Sanofi and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps Paris and Tarrytown, N.Y. – September 30, [removed]Sanofi and Regeneron Pharma

Add to Reading List

Source URL: en.sanofi.com

Language: English - Date: 2014-10-10 07:50:13
32COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent de premiers résultats positifs sur le dupilumab dans le traitement de la polypose naso-sinusienne Paris (France) et Tarrytown (New York) - Le 30 septembre[removed]Sano

COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent de premiers résultats positifs sur le dupilumab dans le traitement de la polypose naso-sinusienne Paris (France) et Tarrytown (New York) - Le 30 septembre[removed]Sano

Add to Reading List

Source URL: www.sanofi.com

Language: French - Date: 2014-10-10 00:22:07
    33November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I

    November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I

    Add to Reading List

    Source URL: files.shareholder.com

    Language: English
    34April 3, 2014 Regeneron Announces Initiative for STEM Education in Hudson Valley Fellowship Program in Collaboration with NASA, Teachers College, Columbia University and STEM Education Leadership Center TARRYTOWN, N.Y.,

    April 3, 2014 Regeneron Announces Initiative for STEM Education in Hudson Valley Fellowship Program in Collaboration with NASA, Teachers College, Columbia University and STEM Education Leadership Center TARRYTOWN, N.Y.,

    Add to Reading List

    Source URL: files.shareholder.com

    Language: English
    35COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent la présentation des résultats positifs détaillés de quatre études pivots sur l’alirocumab au Congrès 2014 de l’ESC - L’alirocumab, un produit expérimental

    COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent la présentation des résultats positifs détaillés de quatre études pivots sur l’alirocumab au Congrès 2014 de l’ESC - L’alirocumab, un produit expérimental

    Add to Reading List

    Source URL: www.sanofi.com

    Language: French - Date: 2014-10-10 05:15:08
      36COMMUNIQUÉ DE PRESSE Sanofi et Regeneron vont présenter les résultats de quatre essais cliniques de Phase 3 consacrés à l’alirocumab à la séance Hot Line du Congrès 2014 de l’ESC Paris (France) et Tarrytown

      COMMUNIQUÉ DE PRESSE Sanofi et Regeneron vont présenter les résultats de quatre essais cliniques de Phase 3 consacrés à l’alirocumab à la séance Hot Line du Congrès 2014 de l’ESC Paris (France) et Tarrytown

      Add to Reading List

      Source URL: www.sanofi.com

      Language: French - Date: 2014-10-10 00:18:53
        37PRESS RELEASE Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 Paris, France, and Tarrytown, NY, August 25, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY)

        PRESS RELEASE Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 Paris, France, and Tarrytown, NY, August 25, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY)

        Add to Reading List

        Source URL: en.sanofi.com

        Language: English - Date: 2014-10-09 14:57:16
        38Sanofi and Regeneron Present Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress[removed]Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C

        Sanofi and Regeneron Present Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress[removed]Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C

        Add to Reading List

        Source URL: en.sanofi.com

        Language: English - Date: 2014-10-10 12:14:27
        39Nueva Droga, Zaltrap, Aprobada por la FDA para Pacientes con Cáncer Metastásico Estadio IV  ¿Qué es Zaltrap? o Zaltrap fue desarrollado por Sanofi en asociación con Regeneron Pharmaceuticals. o Zaltrap es el prim

        Nueva Droga, Zaltrap, Aprobada por la FDA para Pacientes con Cáncer Metastásico Estadio IV  ¿Qué es Zaltrap? o Zaltrap fue desarrollado por Sanofi en asociación con Regeneron Pharmaceuticals. o Zaltrap es el prim

        Add to Reading List

        Source URL: www.ccalliance.org

        Language: Spanish - Date: 2012-08-14 23:27:37
          40July 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis Results from Earlier Clinical Trials Published Today in the New England

          July 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis Results from Earlier Clinical Trials Published Today in the New England

          Add to Reading List

          Source URL: files.shareholder.com

          Language: English